RecruitingNANCT07052916

Pilot Trial of Telehealth Music Therapy for Cognitive Dysfunction in Hematologic Cancer Survivors (PRELUDE)

Sponsor: Memorial Sloan Kettering Cancer Center

Trial Details

ConditionBlood Cancer, Lymphoma, Leukemia, Myeloma
InterventionMusic Therapy/MT; Therapist-Attention Music Education/TAME Control
PhaseNA
StatusRecruiting
Participants60
Est. Completion27 Dec 2026
Last Updated26 May 2026

Primary Outcome

Feasibility of studying a telehealth-based Music Therapy/MT intervention for cancer-related cognitive dysfunction/CRCD in hematologic cancer survivors as defined as the completion of 9 or more sessions.

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * English-proficient, aged 18 or older * Diagnosis of lymphoma, leukemia, or myeloma * Stable oncologic disease or no evidence of disease as indicated in the medical chart or by the oncology team * Score of \<54 on the FACT-Cog PCI subscale * Minimum life expectancy of one year as per clinician assessment * Patient should be able to understand and complete all study assessments on their own. * Eligible patient should be able to understand informed consent and provide signed informed consent in English. Exclusion Criteria: * Less than 3 months since completion of surgery, radiation, induction chemotherapy (for newly diagnosed or relapsed disease), transplantation, or immunotherapy (e.g., CAR T-Cell, bispecific antibodies) * If there is a defined treatment period, the patient must be at least 3 months from treatment completion * If the patient is on continuous therapy, patient must have completed at least 6 months of the therapy * Maintenance therapies are allowed * Received music therapy (MT) in the past year * Current music training, \>6 months of music training in the past 10 years, or plan to initiate music training during the study * No access to an internet-connected device * Active suicidal ideation, bipolar, schizophrenia, or substance abuse * BOMC score ≥10 (indicative of dementia) * Uncorrectable visual, auditory, or motor impairments * Initiation or altered dose of sedative, stimulant, or anti-cholinergic medications in the past month or plan to initiate these medications during the study, as these are known to impact cognitive function * Initiation of any other interventions for CRCD (e.g., cognitive rehabilitation) in the past month or plan to initiate these interventions during the study, as these are known to impact cognitive function

Trial Sites

Countries

United States
View Registry Entry

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service